22:35 , Jul 11, 2019 |  BC Innovations  |  Emerging Company Profile

Twentyeight-Seven's bet on RNA-binding proteins

Twentyeight-Seven is building a small molecule platform to target interactions between non-coding RNAs and an emerging target class in gene regulation: RNA-binding proteins. Launched last September, the company is using an $82.8 million series A...
23:34 , Jul 8, 2019 |  BC Extra  |  Clinical News

July 8 Clinical Quick Takes: Hemophilia data from Sangamo-Pfizer, Novo; plus GamaMabs, Xarelto and more

Sustained Factor VIII levels for Sangamo, Pfizer hemophilia A gene therapy  Sangamo Therapeutics Inc. (NASDAQ:SGMO) and partner Pfizer Inc. (NYSE:PFE) presented data at the International Society on Thrombosis and Haemostasis (ISTH) meeting in Melbourne showing...
00:42 , Jun 22, 2019 |  BioCentury  |  Product Development

Is tau the new amyloid?

After finally getting the message that they need to look beyond amyloid to treat Alzheimer’s disease, pharmas are lining up behind tau as the next big target. The question is whether they can pick out...
23:12 , Jun 18, 2019 |  BC Innovations  |  Distillery Therapeutics

RLN2 injections to treat shoulder arthrofibrosis

DISEASE CATEGORY: Musculoskeletal INDICATION: Musculoskeletal Injections of RLN2 could help treat shoulder arthrofibrosis, which manifests as long-standing restriction of joint range of motion. In a rat model of immobilization-induced shoulder arthrofibrosis, intra-articular injections of RLN2...
22:14 , Jun 14, 2019 |  BioCentury  |  Emerging Company Profile

Sherlock: Leveraging CRISPR, synthetic biology for diagnostics

By taking advantage of two hot technologies, Sherlock is developing a pair of molecular diagnostics that can be used alone or together to rapidly and accurately detect disease in a wide variety of applications. Sherlock...
00:11 , Jun 13, 2019 |  BC Innovations  |  Translation in Brief

New inflammasome structure from Harvard, SMOC fodder for rational drug design

The ability to rationally design small molecules against a highly sought after inflammasome target -- NLRP3 -- got a boost Wednesday when new structural information was published in Nature by a group from Harvard Medical...
21:02 , Jun 6, 2019 |  BC Innovations  |  Emerging Company Profile

Scipher: decoding drug response from protein interactions

To improve the accuracy of therapeutic response predictions, Scipher has incorporated protein-protein interaction maps into its machine learning-based analyses of patient gene expression data to spotlight pathologically relevant markers. According to Scipher Medicine Corp. CEO...
00:45 , Jun 5, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: May 2019

New Therapeutic Targets and Biomarkers: May 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during May. Therapeutic targets are defined as any protein, gene or other molecule...
00:51 , May 31, 2019 |  BC Innovations  |  Targets & Mechanisms

Targeting cancer evolution offers a way to foil drug resistance

A growing crop of researchers and companies are tackling cancer drug resistance by preempting tumors’ tendencies to adapt, rather than responding to resistance after it develops. Though still in their infancy, these therapies could get...
23:31 , May 28, 2019 |  BC Extra  |  Company News

May 28 Company Quick Takes: Viela finds China partner for rare CNS disorder mAb; plus Santhera, Juvenescence’s Souvien and more

Viela partners with Hansoh on mAb for rare CNS disorder in China  Viela Bio Inc. (Gaithersburg, Md.) granted Hansoh Pharmaceutical Group Co. Ltd. (Lianyungang, China) rights to develop and commercialize Viela's humanized anti-CD19 mAb inebilizumab...